after signing the consent form, baseline data are collected, including medical history, current medications, and blood samples to measure cholesterol levels.

the cholesterol measurements include ldl-c (the “bad” cholesterol), hdl-c (the “good” cholesterol), and other lipid values.

the participant is randomly assigned, in a double‑blind manner, to receive either the test medication obicetrapib 10 mg tablet, the comparator medication bempedoic acid 180 mg film‑coated tablet, or the matching placebo for each.

the study medication is taken orally once daily.

the participant ingests one tablet each day for a total of 84 days.

if the assigned tablet is a placebo, it looks identical to the active tablet but does not contain the active ingredient.

follow‑up visits occur at approximately day 28, day 56, and day 84 after the first dose.

each visit includes a brief physical examination, vital‑sign check, and blood draw to repeat the cholesterol measurements.

the visits also include assessment of any adverse events (possible side effects) and review of concomitant medications.

on day 84 the change in ldl-c from the baseline value is calculated to determine the primary efficacy outcome.

additional lipid parameters (such as non‑hdl‑c, hdl‑c, apoa1, apob, lpa, and triglycerides) are also evaluated.

after the final assessments, the participant stops the study medication.

the participant continues any previously prescribed lipid‑lowering therapy as directed by the regular health‑care provider.